NCT00735787

Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.

Conditions

• Psoriasis

Interventions

Type	Name	Description
BIOLOGICAL	Placebo	Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
BIOLOGICAL	Adalimumab	Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.

Timeline

• Start date: 2008-08-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2008-08-15
• Last updated: 2010-11-01
• Results posted: 2010-11-01

Locations

17 sites across 2 countries: United States, Canada